Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 11/20 | 0.88 |
| ▸ | CACNA1D | Q01668 | 11/20 | 0.88 |
| ▸ | CACNA1S | Q13698 | 11/20 | 0.88 |
| ▸ | CACNA1C | Q13936 | 11/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.85 |
| ▸ | MEN1 | O00255 | 4/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.79 |
| ▸ | THPO | P40225 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7275184 | 0.97 | CACNA1F (0.82) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL3433831 | 0.94 | CACNA1F (0.88) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL3435101 | 0.93 | HIF1A (0.81) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7430479 | 0.93 | MEN1 (0.80) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7275191 | 0.93 | CACNA1F (0.76) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7275200 | 0.93 | CACNA1F (0.76) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL2574894 | 0.92 | CACNA1F (1.00) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL10823969 | 0.92 | CACNA1F (0.85) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL10824020 | 0.91 | CACNA1F (0.87) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 | |
| SCHEMBL7282379 | 0.91 | CACNA1F (0.76) | CACNA1FCACNA1DCACNA1SCACNA1CADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163907-B2 | Dihydropyridine calcium antagonist compounds, preparation methods, and medical uses thereof | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2012-04-24 | — | — | US | disclosed |
| US-8163907-B2 | Dihydropyridine calcium antagonist compounds, preparation methods, and medical uses thereof | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2012-04-24 | — | — | US | disclosed |
| US-20110201811-A1 | DIHYDROPYRIDINE CALCIUM ANTAGONIST COMPOUNDS, PREPARATION METHODS, AND MEDICAL USES THEREOF | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2011-08-18 | — | — | US | disclosed |
| US-20110201811-A1 | DIHYDROPYRIDINE CALCIUM ANTAGONIST COMPOUNDS, PREPARATION METHODS, AND MEDICAL USES THEREOF | COSUNTER PHARMACEUTICAL COMPANY (CN) | 2011-08-18 | — | — | US | disclosed |
| US-5591757-A | ADRENERGIC BETA-RECEPTOR BLOCKING AGENTS AND CALCIUM ANTAGONIST | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| US-5110820-A | Hypotensive agents; cardiovascular disorders | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0151006-B1 | DIHYDROPYRIDINE COMPOUNDS, THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF PRODUCING THESE COMPOSITIONS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4894460-A | 1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID ESTERS | PIERREL S.P.A. (IT) | 1990-01-16 | — | — | US | disclosed |
| US-4772621-A | Antihypertensive diphenylpropyl aminopropyl ester of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1988-09-20 | — | — | US | disclosed |
| US-4705797-A | HYPOTENSIVE AGENTS, VASODILATORS | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1987-11-10 | — | — | US | disclosed |
| EP-0153016-A2 | Asymmetrical diesters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1985-08-28 | — | — | EP | disclosed |
| EP-0151006-A2 | Dihydropyridine compounds, their production, pharmaceutical compositions containing them, and methods of producing these compositions | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1985-08-07 | — | — | EP | disclosed |
| EP-0097821-A2 | Dihydropyridines with an antagonistic activity to calcium, process for their preparation, and pharmaceutical compositions containing them | Pierrel S.p.A. (IT) | 1984-01-11 | — | — | EP | disclosed |
| US-3985758-A | 1,4-Dihydropyridine derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201811-A1 | DIHYDROPYRIDINE CALCIUM ANTAGONIST COMPOUNDS, PREPARATION METHODS, AND MEDICAL USES THEREOF | RYR1, CACNA1E, CACNA1C | CACNA1F 8/4885CACNA1D 9/4885CACNA1S 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.